Revelation Biosciences Presents Positive Data for Gemini at International Conference
Revelation Biosciences presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology in San Diego. Presented data demonstrated the capability of Gemini to normalize the hyperinflammatory state and restore immunocompetence up to 7 days after a single dose, in stage 3 and 4 chronic kidney disease patients peripheral blood mononuclear cells. Gemini is the Company's proprietary formulation of phosphorylated hexaacyl disaccharide, a toll-like receptor 4 agonist, in development for the treatment of acute and chronic inflammation-driven diseases such as acute kidney injury and CKD. In the PRIME study, a majority of patients had at least one elevated cytokine predose and of these patients had elevated inflammatory cytokines IL-1b and IL-6. Treatment with Gemini significantly reduced the number of elevated cytokines at all measured timepoints post-dose out to 7 days following a single dose of Gemini verses no significant change in placebo. In addition, a majority of patients were also found to be non-responsive to stimulation predose. Gemini significantly restored normal responsiveness to LPS stimulation and trended to improved responsiveness to HMGB1. No significant responses were observed for placebo.
